Activase® is the standard of care for treating eligible patients with acute ischemic stroke (AIS) within 3 hours of symptom onset 2 

Review AHA/ASA stroke treatment guidelines

The American Heart Association/American Stroke Association (AHA/ASA) practice guidelines recommend Activase for treatment of AIS:

  • Intravenous Activase (0.9 mg/kg, maximum dose 90 mg) is recommended for selected patients who may be treated within 3 hours of ischemic stroke onset (Class 1; Level of Evidence A, 2013 AHA/ASA Guidelines) 2
  • The benefit of Activase therapy is time-dependent, and treatment should be initiated as quickly as possible in eligible patients. The door-to-needle (DTN) time (time of bolus administration) should be within 60 minutes of hospital arrival (Class 1; Level of Evidence A, 2013 AHA/ASA Guidelines) 2
  • According to the 2013 AHA/ASA Guidelines to assess patients with suspected AIS, the following diagnostic tests must be performed immediately 2:
    • Non-contrast brain computed tomography (CT) or brain magnetic resonance imaging (MRI)
    • Blood glucose
    • Oxygen saturation


  • In 1996, the FDA approved the intravenous recombinant tissue plasminogen activator (tPA) Activase® for acute ischemic stroke. Today, it remains the only medication proven to affect outcomes when administered within the recommended time frame after ischemic stroke. 3


  • The FDA stated that “tPA” is the abbreviation for the drug class that encompasses all tissue plasminogen activators. To avoid confusion and medication errors, it has directed healthcare professionals to use either the brand name, Activase, or the generic name, alteplase, in written prescriptions and verbal orders. 4